FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a compound of macrophage inhibiting cytokine-1 (hereinafter – MIC-1) consisting of MIC-1 polypeptide and N-end elongation of an amino acid sequence; it can be used in medicine.
EFFECT: obtained compound containing an amino acid sequence selected from SEQ ID NO: 89-117, 164, 165, 182, 200-221 can be used for the effective prevention or treatment of obesity.
2 cl, 5 dwg, 15 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| CD3-EPSILON-BINDING DOMAIN WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2769948C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
